Clinical Trials Arena December 22, 2025
From tariffs and onshoring to MFN, the US has seen significant policy developments – but how will these impact pharma in 2026?
After President Donald Trump’s administration took office in early 2025, a series of policy changes have directly impacted the pharma sector.
From tariffs and onshoring initiatives to Most Favored Nation (MFN) agreements, companies are adjusting their practices to strengthen their position in the lucrative US market.
Given the scale of these developments, CEOs and executives are closely monitoring the news, says Kit Conklin, senior vice president of Risk & Compliance at Exiger, and an advisor involved in the creation of the BIOSECURE Act.
“I don’t have to educate executives about policy issues anymore. It’s been an eye-opening year...
Today's Sponsors
Today's Sponsor